Why the study?
CMR performed early after STEMI can improve MACE risk prediction, prompting the development of a simple clinical-CMR risk score for early risk stratification.
Does a combined clinical-CMR risk score predict MACE in reperfused STEMI patients?
Population
1118 reperfused STEMI patients
Design
Multicenter prospective registry
Follow-up
Median 5.52 [2.63-7.44] years
Key result
A novel 8-point clinical-CMR risk score stratified MACE risk early after STEMI, with rates of 1.96, 5.44, and 19.7 per 100 person-years in low, intermediate, and high-risk categories (p<0.001).
Authors
Loading...
May aid post-STEMI risk stratification; hypothesis-generating pending prospective validation.
Cohort (n=1,118)
Yes
Does a combined clinical-CMR risk score predict MACE in reperfused STEMI patients?
p-value: p=< 0.001
A novel 8-point risk score combining clinical and CMR variables effectively stratifies long-term MACE risk in patients early after reperfused STEMI.
Marcos‐Garcés et al. (2021) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=1,118). Clinical-CMR risk score was evaluated on Major adverse cardiac events (cardiovascular death, non-fatal myocardial infarction, or re-admission for acute decompensated heart failure) (p=< 0.001). A novel 8-point clinical-CMR risk score stratified MACE risk early after STEMI, with rates of 1.96, 5.44, and 19.7 per 100 person-years in low, intermediate, and high-risk categories (p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: